Skip to main content

Table 1 Clinicopathological characteristics of the patients with EOC

From: FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma

 

Mean or number

Range or percentage

Age at diagnosis (years)

57 ± 11.85

16–87

Menopause status

 Pre-menopause

33

26%

 Post-menopause

94

74%

Family history of cancer

 Yes

7

5.5%

 No

120

94.5%

Preoperative CA125 level (IU/ml)

1254.51 ± 2579.66

9.53–17,980

FIGO stage

 Stage I

35

27.6%

 Stage II

9

7.1%

 Stage III

69

54.3%

 Stage IV

14

11.0%

Pathological pattern

 Serous

90

70.9%

 Mucinous

7

5.5%

 Clear cell

21

16.5%

 Endometrioid

9

7.1%

Lymphatic metastasis

 Yes

47

37.0%

 No

80

63.0%

Current status

 NED

65

51.2%

 AWD

19

15.0%

 DOD

43

33.9%

 PFS (months)

32.598 ± 23.0

4–109

 OS (months)

40.448 ± 24.5

4–109

  1. FIGO International Federation of Gynecology and Obstetrics, NED no evidence of disease, AWD alive with disease, DOD die of disease